Toward an Extensible Regulatory Framework for N-of-1 to N-of-Few Personalized RNA Therapy Design
Therapeutic Innovation & Regulatory Science · 2025-05 · 59 (3) · 505-518
DOI: 10.1007/s43441-025-00752-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 27.02.2025. Verfasst von Mélissa Bou-Jaoudeh und 3 weiteren Autor:innen. Beteiligte Einrichtung: ProductLife Group, Courbevoie, France. mboujaoudeh@productlife-group.com. Hauptthemen laut MEDLINE: Precision Medicine, RNA, Rare Diseases, Genetic Therapy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The emergence of personalized RNA therapeutics, tailored to individual patients' genetic profiles, offers new hope for treating both common and rare diseases. This review explores regulatory aspects of N-of-1 and N-of-few approaches, providing promising treatments for ultra- or nano-rare diseases that lack established therapies. These diseases present unique challenges, as patients may represent the sole individual or a small group worldwide with a specific mutation, necessitating personalized approaches to treatment development, validation, and approval. While progress is promising, the regulatory landscape remains nascent, raising challenges in ensuring safety and industry sustainability. Artificial intelligence (AI) and automated systems, coupled with real-world evidence (RWE) monitoring, offer significant potential to address these challenges by optimizing development, manufacturing, and regulatory compliance. Drawing parallels from other regulatory domains, this review presents a design envelope framework, integrated with AI tools, to streamline the approval process and enhance the adaptability of RNA-based treatments. Case studies of individualized RNA-based treatments highlight successes and setbacks, underscoring the need for regulatory alignment. Collaborative efforts from stakeholders and regulatory authorities are essential to refine this framework for real-world application. Overall, this review emphasizes the transformative potential of personalized RNA therapeutics in advancing precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ProductLife Group, Courbevoie, France. mboujaoudeh@productlife-group.com.
- ProductLife Group, Courbevoie, France.
- Carl Gustav Carus University Hospital Dresden, Dresden University of Technology, Dresden, Germany.
- Else Kröner Fresenius Center for Digital Health, TUD Dresden University of Technology, Dresden, Germany.
Zitieren
APA
Bou-Jaoudeh, M., Piaton-Breda, G., Pereme, F., & Gilbert, S. (2025). Toward an Extensible Regulatory Framework for N-of-1 to N-of-Few Personalized RNA Therapy Design. Therapeutic Innovation & Regulatory Science, 59(3), 505-518. https://doi.org/10.1007/s43441-025-00752-8
Vancouver
Bou-Jaoudeh M, Piaton-Breda G, Pereme F, Gilbert S. Toward an Extensible Regulatory Framework for N-of-1 to N-of-Few Personalized RNA Therapy Design. Therapeutic Innovation & Regulatory Science. 2025;59(3):505-518. doi:10.1007/s43441-025-00752-8
BibTeX
@article{BouJaoudeh2025,
author = {Bou-Jaoudeh, Mélissa and Piaton-Breda, Gabriele and Pereme, Florian and Gilbert, Stephen},
title = {Toward an Extensible Regulatory Framework for N-of-1 to N-of-Few Personalized RNA Therapy Design},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2025},
volume = {59},
number = {3},
pages = {505--518},
doi = {10.1007/s43441-025-00752-8}
}
EUVIMED